Amgen Inc. $AMGN Shares Purchased by NEOS Investment Management LLC

NEOS Investment Management LLC boosted its stake in Amgen Inc. (NASDAQ:AMGN) by 10.8% during the second quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 409,827 shares of the medical research company’s stock after buying an additional 39,887 shares during the quarter. NEOS Investment Management LLC owned approximately 0.08% of Amgen worth $148,407,000 as of its most recent filing with the SEC.

A number of other large investors have also recently bought and sold shares of AMGN. Rational Advisors Inc. raised its holdings in shares of Amgen by 13.7% in the second quarter. Rational Advisors Inc. now owns 199 shares of the medical research company’s stock worth $72,000 after acquiring an additional 24 shares during the last quarter. Beacon Financial Advisory LLC boosted its stake in shares of Amgen by 2.0% during the second quarter. Beacon Financial Advisory LLC now owns 1,274 shares of the medical research company’s stock valued at $461,000 after acquiring an additional 25 shares during the last quarter. Legacy Financial Advisors Inc. increased its position in Amgen by 0.8% during the 2nd quarter. Legacy Financial Advisors Inc. now owns 3,407 shares of the medical research company’s stock worth $1,234,000 after purchasing an additional 26 shares in the last quarter. Roman Butler Fullerton & Co. increased its position in Amgen by 1.4% during the 2nd quarter. Roman Butler Fullerton & Co. now owns 1,956 shares of the medical research company’s stock worth $705,000 after purchasing an additional 27 shares in the last quarter. Finally, High Note Wealth LLC raised its stake in Amgen by 5.8% in the 4th quarter. High Note Wealth LLC now owns 508 shares of the medical research company’s stock valued at $166,000 after purchasing an additional 28 shares during the last quarter. Institutional investors and hedge funds own 76.50% of the company’s stock.

Insider Activity at Amgen

In other Amgen news, SVP Nancy Grygiel sold 2,970 shares of the stock in a transaction that occurred on Thursday, August 6th. The shares were sold at an average price of $402.16, for a total transaction of $1,194,415.20. Following the transaction, the senior vice president owned 7,340 shares of the company’s stock, valued at $2,951,854.40. This trade represents a 28.81% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, SVP Rachna Khosla sold 2,000 shares of Amgen stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $412.57, for a total transaction of $825,140.00. Following the completion of the transaction, the senior vice president owned 6,404 shares in the company, valued at approximately $2,642,098.28. This trade represents a 23.80% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 6,222 shares of company stock valued at $2,540,926 in the last ninety days. 0.85% of the stock is currently owned by company insiders.

Amgen Stock Up 0.3%

Shares of NASDAQ:AMGN opened at $444.12 on Friday. The company has a current ratio of 1.37, a quick ratio of 1.13 and a debt-to-equity ratio of 4.44. The firm has a market cap of $240.11 billion, a price-to-earnings ratio of 27.60, a PEG ratio of 3.19 and a beta of 0.43. The stock’s 50-day moving average price is $395.82 and its two-hundred day moving average price is $366.66. Amgen Inc. has a 12-month low of $269.77 and a 12-month high of $447.03.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Tuesday, August 4th. The medical research company reported $6.29 EPS for the quarter, beating analysts’ consensus estimates of $5.62 by $0.67. The company had revenue of $10.05 billion during the quarter, compared to the consensus estimate of $9.43 billion. Amgen had a net margin of 22.95% and a return on equity of 124.14%. The company’s quarterly revenue was up 9.5% compared to the same quarter last year. During the same quarter in the prior year, the company posted $6.02 EPS. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. On average, research analysts forecast that Amgen Inc. will post 22.97 EPS for the current year.

Amgen Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, September 11th. Investors of record on Friday, August 21st will be given a dividend of $2.52 per share. The ex-dividend date of this dividend is Friday, August 21st. This represents a $10.08 annualized dividend and a yield of 2.3%. Amgen’s dividend payout ratio is 62.65%.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on AMGN. Oppenheimer upped their target price on shares of Amgen from $400.00 to $450.00 and gave the company an “outperform” rating in a report on Wednesday, August 5th. The Goldman Sachs Group set a $389.00 price target on shares of Amgen in a report on Friday, June 5th. TD Cowen boosted their price objective on shares of Amgen from $420.00 to $452.00 and gave the company a “buy” rating in a research report on Wednesday, August 5th. Canaccord Genuity Group upped their price objective on shares of Amgen from $366.00 to $384.00 and gave the company a “hold” rating in a research note on Wednesday, August 5th. Finally, Truist Financial lifted their target price on shares of Amgen from $340.00 to $362.00 and gave the stock a “hold” rating in a research note on Wednesday, August 5th. One research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, thirteen have assigned a Hold rating and three have given a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $380.43.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.